Prediction models based on KIF4A expression can reliably predict tumour cell sensitivity to platinum-based agents, taxanes, and topoisomerase inhibitors, achieving an area under the curve (AUC) exceeding 0.85, thus providing a valuable tool for personalized chemotherapy regimens [138]. Here, KIF4A is linked to neoplasm.